• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit.

作者信息

Urbaniak-Kujda Donata, Biernat Monika Maria, Skalec Tomasz, Jacków-Nowicka Jagoda, Windyga Jerzy, Wróbel Tomasz

机构信息

Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.

Department of Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Wrocław, Poland.

出版信息

Haemophilia. 2021 Jul;27(4):e567-e570. doi: 10.1111/hae.14326. Epub 2021 Apr 29.

DOI:10.1111/hae.14326
PMID:33915601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8239651/
Abstract
摘要

相似文献

1
Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit.在重症监护病房中，一名接受emicizumab预防治疗的重度甲型血友病患者的新型冠状病毒肺炎得到成功治疗。
Haemophilia. 2021 Jul;27(4):e567-e570. doi: 10.1111/hae.14326. Epub 2021 Apr 29.
2
Management of COVID-19-associated coagulopathy in persons with haemophilia.COVID-19 相关凝血病的管理：血友病患者篇
Haemophilia. 2021 Jan;27(1):41-48. doi: 10.1111/hae.14191. Epub 2020 Nov 20.
3
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.COVID-19 合并严重甲型血友病患者接受emicizumab 预防治疗后的血栓预防
J Thromb Haemost. 2020 Sep;18(9):2202-2204. doi: 10.1111/jth.14954. Epub 2020 Jul 6.
4
Therapeutic choices in persons with haemophilia at the time of COVID-19.新冠疫情期间血友病患者的治疗选择
Blood Transfus. 2020 Jul;18(4):326-327. doi: 10.2450/2020.0154-20.
5
Successful in-patient management of COVID-19 infection in an old severe haemophilia A patient on emicizumab with multiple prothrombotic comorbidities.在一名患有多种血栓形成合并症的老年重度甲型血友病患者中，使用emicizumab成功进行COVID-19感染的住院治疗。
Haemophilia. 2023 Mar;29(2):674-675. doi: 10.1111/hae.14743. Epub 2023 Jan 14.
6
Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era.新冠疫情时代血友病治疗新疗法的利弊
Blood Transfus. 2021 Jan;19(1):73-76. doi: 10.2450/2020.0241-20. Epub 2020 Sep 18.
7
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.双特异性抗体emicizumab 治疗 A 型血友病：抑制剂患者的突破。
BioDrugs. 2018 Dec;32(6):561-570. doi: 10.1007/s40259-018-0315-0.
8
Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor.艾美赛珠单抗预防治疗以促进抗凝治疗用于伴有抑制剂的重度血友病患者心房内血栓形成的管理。
Haemophilia. 2019 May;25(3):e203-e205. doi: 10.1111/hae.13721. Epub 2019 Mar 13.
9
Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study.儿童血友病中依库珠单抗的应用：一项单中心回顾性研究中的出血和手术结局。
Pediatr Blood Cancer. 2021 Nov;68(11):e29325. doi: 10.1002/pbc.29325. Epub 2021 Sep 7.
10
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.艾美赛珠单抗在血友病 A 患者中的真实世界应用：出血结局和手术操作。
Haemophilia. 2020 Jul;26(4):631-636. doi: 10.1111/hae.14005. Epub 2020 Apr 20.

本文引用的文献

1
Management of COVID-19-associated coagulopathy in persons with haemophilia.COVID-19 相关凝血病的管理：血友病患者篇
Haemophilia. 2021 Jan;27(1):41-48. doi: 10.1111/hae.14191. Epub 2020 Nov 20.
2
Management of COVID-19 Coagulopathy in a Patient with Severe Haemophilia A.COVID-19 相关凝血功能障碍的管理：重型甲型血友病患者的处理。
Acta Haematol. 2021;144(3):319-321. doi: 10.1159/000510591. Epub 2020 Sep 25.
3
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals.COVID-19 在良性血液学中的表现：医疗专业人员面临的新挑战和特殊考虑因素。
Expert Rev Hematol. 2020 Oct;13(10):1081-1092. doi: 10.1080/17474086.2020.1819785. Epub 2020 Sep 15.
4
Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)?先天性出血性疾病患者似乎受严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的影响较小：遗传性低凝状态是否克服了2019冠状病毒病（COVID-19）的获得性高凝状态？
Semin Thromb Hemost. 2020 Oct;46(7):853-855. doi: 10.1055/s-0040-1713435. Epub 2020 Jun 18.
5
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.COVID-19 合并严重甲型血友病患者接受emicizumab 预防治疗后的血栓预防
J Thromb Haemost. 2020 Sep;18(9):2202-2204. doi: 10.1111/jth.14954. Epub 2020 Jul 6.
6
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
7
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
8
Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor.艾美赛珠单抗预防治疗以促进抗凝治疗用于伴有抑制剂的重度血友病患者心房内血栓形成的管理。
Haemophilia. 2019 May;25(3):e203-e205. doi: 10.1111/hae.13721. Epub 2019 Mar 13.
9
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.